{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Statins+%28atorvastatin+or+simvastatin%29", "query": { "intervention": "Statins (atorvastatin or simvastatin)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Statins+%28atorvastatin+or+simvastatin%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T15:28:54.074Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02072161", "title": "Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "ETC-1002", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Statin Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Esperion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 133, "start_date": "2014-03", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2019-03-29", "last_synced_at": "2026-10-05T15:28:54.074Z", "location_count": 40, "location_summary": "Muscle Shoals, Alabama • Chandler, Arizona • Chino, California + 36 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Chino", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02072161" }, { "nct_id": "NCT02850081", "title": "Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carotid Artery Stenosis", "Strokes" ], "interventions": [ { "name": "Statin", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2017-06-01", "completion_date": "2020-03-31", "has_results": true, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-05T15:28:54.074Z", "location_count": 7, "location_summary": "Ridgewood, New Jersey • Albany, New York • Buffalo, New York + 1 more", "locations": [ { "city": "Ridgewood", "state": "New Jersey" }, { "city": "Albany", "state": "New York" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02850081" }, { "nct_id": "NCT01954394", "title": "Open Label Study of Long Term Safety Evaluation of Alirocumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Lipid-Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 986, "start_date": "2013-12-17", "completion_date": "2017-06-30", "has_results": true, "last_update_posted_date": "2018-07-24", "last_synced_at": "2026-10-05T15:28:54.074Z", "location_count": 44, "location_summary": "Huntsville, Alabama • Tempe, Arizona • Bell Gardens, California + 39 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Bell Gardens", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01954394" }, { "nct_id": "NCT01617655", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2012-06", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-10-05T15:28:54.074Z", "location_count": 14, "location_summary": "Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more", "locations": [ { "city": "Bell Gardens", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01617655" }, { "nct_id": "NCT00491530", "title": "A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mixed Dyslipidemia" ], "interventions": [ { "name": "ABT-335", "type": "DRUG" }, { "name": "rosuvastatin calcium", "type": "DRUG" }, { "name": "simvastatin", "type": "DRUG" }, { "name": "atorvastatin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 310, "start_date": "2007-06", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2012-01-20", "last_synced_at": "2026-10-05T15:28:54.074Z", "location_count": 1, "location_summary": "Abbott Park, Illinois", "locations": [ { "city": "Abbott Park", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00491530" }, { "nct_id": "NCT01644188", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo (for ezetimibe)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 720, "start_date": "2012-08", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2016-08-04", "last_synced_at": "2026-10-05T15:28:54.074Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644188" }, { "nct_id": "NCT01507831", "title": "Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Alirocumab", "type": "DRUG" }, { "name": "Lipid-Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2341, "start_date": "2012-01", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2015-12-22", "last_synced_at": "2026-10-05T15:28:54.074Z", "location_count": 115, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Sierra Vista, Arizona + 90 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Sierra Vista", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01507831" }, { "nct_id": "NCT01222182", "title": "Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "atorvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": null, "sex": "ALL", "summary": "25 Years and older" }, "enrollment_count": 260, "start_date": "2009-09", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2012-05-28", "last_synced_at": "2026-10-05T15:28:54.074Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222182" }, { "nct_id": "NCT00687076", "title": "Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Peripheral Arterial Disease" ], "interventions": [ { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Niaspan", "type": "DRUG" }, { "name": "Statin therapy", "type": "DRUG" }, { "name": "Standard care", "type": "BEHAVIORAL" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "Clopidogrel", "type": "DRUG" }, { "name": "Placebo Niaspan", "type": "DRUG" }, { "name": "Placebo Ezetimibe", "type": "DRUG" }, { "name": "Percutaneous transluminal angioplasty (PTA)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "PROCEDURE" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 102, "start_date": "2004-04", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2020-02-06", "last_synced_at": "2026-10-05T15:28:54.074Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00687076" }, { "nct_id": "NCT01105975", "title": "A Study of LY2484595 in Patients With High LDL-C or Low HDL-C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dyslipidemia" ], "interventions": [ { "name": "LY2484595", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Placebo for LY2484595", "type": "DRUG" }, { "name": "Placebo for Statins", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 398, "start_date": "2010-04", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2018-03-22", "last_synced_at": "2026-10-05T15:28:54.074Z", "location_count": 38, "location_summary": "Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Spring Valley", "state": "California" }, { "city": "Vista", "state": "California" }, { "city": "Golden", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01105975" } ] }